Pyrosequencing™-based screening for the genetic polymorphism CYP2B6 1459 C>T

被引：0
|
作者：
Doehring, Alexandra [1 ]
Loetsch, Joern [1 ]
机构：
[1] Goethe Univ Frankfurt, Pharmazentrum Frankfurt ZAFES, Inst Clin Pharmacol, D-60590 Frankfurt, Germany
来源：
PHARMACOGENOMICS | 2009年 / 10卷 / 10期
关键词：
CYTOCHROME P4502B6; THERAPY;
D O I：
10.2217/PGS.09.123
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
引用
收藏
页码：1577 / 1579
页数：3
相关论文
共 50 条
  • [1] Allelic and Genotype Frequencies of CYP2B6*2 (64C > T) and CYP2B6*3 (777C > A) in Three Dominant Ethnicities of the Iranian Population
    Khavandegar, Armin
    Tavakoli-Far, Bahareh
    Ansari, Sarina
    Veis-Karami, Parisa
    Ghasemi, Faezeh
    Sheibaninia, Samira
    Jazayeri, Roshanak
    Houshmand, Massoud
    GENETICS RESEARCH, 2023, 2023
  • [2] CYP2B6 c.983T>C polymorphism is associated with nevirapine hypersensitivity in Malawian and Ugandan HIV populations
    Carr, Daniel F.
    Chaponda, Mas
    Castro, Elena M. Cornejo
    Jorgensen, Andrea L.
    Khoo, Saye
    Van Oosterhout, Joep J.
    Dandara, Collet
    Kampira, Elizabeth
    Ssali, Francis
    Munderi, Paula
    Lalloo, David G.
    Heyderman, Robert S.
    Pirmohamed, Munir
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2014, 69 (12) : 3329 - 3334
  • [3] Comparison of the TaqMan and LightCycler systems in evaluation of CYP2B6 516G>T polymorphism
    Chantarangsu, Soranun
    Cressey, Tim
    Mahasirimongkol, Surakameth
    Tawon, Yardpiroon
    Ngo-Giang-Huong, Nicole
    Jourdain, Gonzague
    Lallemant, Marc
    Chantratita, Wasun
    MOLECULAR AND CELLULAR PROBES, 2007, 21 (5-6) : 408 - 411
  • [4] Effect of genetic polymorphism of human CYP2B6 on the metabolic activation of chlorpyrifos
    Imaishi, Hiromasa
    Goto, Tatsushi
    PESTICIDE BIOCHEMISTRY AND PHYSIOLOGY, 2018, 144 : 42 - 48
  • [5] IMPLICATIONS OF SCREENING FOR CYP2B6 516G>T SNP ON HIV/AIDS PATIENTS
    Swart, M.
    Dandara, C.
    BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, 2014, 115 : 163 - 164
  • [6] Aberrant splicing caused by single nucleotide polymorphism c.516G> T [Q172H], a marker of CYP2B6*6, is responsible for decreased expression and activity of CYP2B6 in liver
    Hofmann, Marco H.
    Blievernicht, Julia K.
    Klein, Kathrin
    Saussele, Tanja
    Schaeffeler, Elke
    Schwab, Matthias
    Zanger, Ulrich M.
    JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2008, 325 (01): : 284 - 292
  • [7] GENETIC POLYMORPHISM OF CYP2B6 AFFECTS THE PHARMACOKINETICS OF SIBUITRAMINE'S METABOLITE
    Cho, M. S.
    Jang, S.
    Lee, Y.
    Lim, L.
    Park, K.
    Chung, J.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2010, 87 : S53 - S53
  • [8] CYP2B6 18492T→C Polymorphism Compromises Efavirenz Concentration in Coinfected HIV and Tuberculosis Patients Carrying CYP2B6 Haplotype*1/*1
    Manosuthi, Weerawat
    Sukasem, Chonlaphat
    Thongyen, Supeda
    Nilkamhang, Samruay
    Manosuthi, Sukanya
    Sungkanuparph, Somnuek
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2014, 58 (04) : 2268 - 2273
  • [9] Influence of the CYP2B6 polymorphism on the pharmacokinetics of mitotane
    D'Avolio, Antonio
    De Francia, Silvia
    Basile, Vittoria
    Cusato, Jessica
    De Martino, Francesca
    Pirro, Elisa
    Piccione, Francesca
    Ardito, Arianna
    Zaggia, Barbara
    Volante, Marco
    Di Perri, Giovanni
    Terzolo, Massimo
    PHARMACOGENETICS AND GENOMICS, 2013, 23 (06): : 293 - 300
  • [10] Population Differences in the Genetic Polymorphism of CYP2B6 May Impact on the Pharmacology of MMT
    Nurfadhlina, M.
    Nasir, M.
    Darussalam, B.
    Azhar, M. Y. M.
    Tan, S. C.
    Ismail, R.
    PUBLIC HEALTH GENOMICS, 2015, 18 : 12 - 12
12345